Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. Since its initial U.S. approval in 2012, Vascepa has received marketing authorizations in key markets including Canada, the European Union and Japan, often through strategic partnerships with regional pharmaceutical companies. Amarin manages its own commercial organization in the United States and leverages licensing agreements to support distribution and patient access abroad.

In addition to its marketed portfolio, Amarin is conducting ongoing research to explore new indications for Vascepa and to expand its understanding of lipid-modifying therapies. Its clinical programs aim to investigate potential benefits in a range of cardiovascular and metabolic conditions. The company operates with a leadership team comprised of seasoned professionals in biopharmaceutical R&D, regulatory affairs and commercial strategy, supported by research facilities in the United States and Europe.

Key Stats

• Today's Range: $15.26 to $15.63
• 50-Day Range: $13.81 to $15.24
• 52-Week Range: $12.30 to $20.90
• Volume: 57,418 shs
• Average Volume: 78,118 shs
• Market Capitalization: $322.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Sell

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 10% of companies evaluated by MarketBeat, and ranked 832nd out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Sell

Consensus Rating

Amarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.

Downside Risk

Amarin has a consensus price target of $12.00, representing about 21.9% downside from its current price of $15.37.

Amount of Analyst Coverage

Amarin has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amarin are expected to grow in the coming year, from ($1.15) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -23.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -23.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.11% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 14.85, which indicates bearish sentiment.

Change versus previous month

Short interest in Amarin has recently increased by 0.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.89

News Sentiment

Amarin has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Amarin this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.21% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

22.25% of the stock of Amarin is held by institutions.

Company Calendar

• Last Earnings: 2/25/2026
• Today: 6/15/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 360
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: -21.9%
• Consensus Rating: Sell
• Rating Score (0-4): 1.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.80 million
• Net Margins: -15.51%
• Pretax Margin: -14.37%
• Return on Equity: -2.99%
• Return on Assets: -2.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.48
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $213.65 million
• Price / Sales: 1.51
• Cash Flow: $0.36 per share
• Price / Cash Flow: 42.22
• Book Value: $22.07 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 20,970,000
• Free Float: 20,086,000
• Market Cap: $322.25 million
• Optionable: Optionable
• Beta: 0.82